Vikas Sinha - 28 Jul 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Officer Title: President and Chief Financial Officer, Director, 10%+ Owner
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
ALVR
Transactions as of
28 Jul 2022
Transactions value $
$15,000,000
Form type
4
Filing time
01 Aug 2022, 16:38:43 UTC
Previous filing
21 Jul 2022
Next filing
17 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $14,999,999 +3,253,796 +24.24% $4.61 16,674,766 28 Jul 2022 By ElevateBio LLC F1, F2
holding ALVR Common Stock 938,224 28 Jul 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.
F2 Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Officer Title: President and Chief Financial Officer